Virbac SA
PAR:VIRP

Watchlist Manager
Virbac SA Logo
Virbac SA
PAR:VIRP
Watchlist
Price: 356.5 EUR 0.14% Market Closed
Market Cap: 3B EUR

Virbac SA
Pre-Tax Income

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Virbac SA
Pre-Tax Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Pre-Tax Income CAGR 3Y CAGR 5Y CAGR 10Y
Virbac SA
PAR:VIRP
Pre-Tax Income
€529m
CAGR 3-Years
47%
CAGR 5-Years
39%
CAGR 10-Years
26%
Sanofi SA
PAR:SAN
Pre-Tax Income
€13.2B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Ipsen SA
PAR:IPN
Pre-Tax Income
€567.9m
CAGR 3-Years
-14%
CAGR 5-Years
N/A
CAGR 10-Years
13%
Vetoquinol SA
PAR:VETO
Pre-Tax Income
€81.9m
CAGR 3-Years
5%
CAGR 5-Years
13%
CAGR 10-Years
7%
Boiron SA
PAR:BOI
Pre-Tax Income
€25.4m
CAGR 3-Years
-30%
CAGR 5-Years
-16%
CAGR 10-Years
-16%
Medincell SA
PAR:MEDCL
Pre-Tax Income
-€18.3m
CAGR 3-Years
10%
CAGR 5-Years
3%
CAGR 10-Years
N/A
No Stocks Found

Virbac SA
Glance View

Founded in 1968 in the picturesque city of Carros near Nice, France, Virbac SA has grown to become a formidable player in the animal health industry. With its roots firmly planted in the niche of veterinary medicine, the company was established by Pierre-Richard Dick, a veterinarian himself, who sought to fill a gap in high-quality veterinary products. Today, Virbac stands as one of the largest independent veterinary pharmaceutical companies, with an extensive global presence spanning more than 100 countries. The company’s portfolio is diverse, encompassing products for both livestock and pets, including vaccines, antibiotics, and specialty diets designed to enhance animal health and welfare. By focusing on R&D and maintaining robust relationships with veterinary professionals, Virbac continually develops solutions that address the evolving needs of animal care. Virbac’s business model revolves around an intricate balance of innovation and strategic market expansion. The company's revenue streams derive from its comprehensive range of products aimed at disease prevention and treatment, which serve various species such as cattle, swine, poultry, horses, cats, and dogs. By investing significantly in research and development, Virbac not only stays ahead in terms of product efficacy and safety but also navigates the regulatory landscapes across its operating regions. This drive to innovate is coupled with a meticulous marketing strategy that involves educating veterinary professionals and end-users, ensuring the optimal use of their products. As a result, Virbac successfully generates income through the direct sale of its products to veterinary clinics, distributors, and directly to pet owners, continually reinforcing its role as a trusted partner in animal health care globally.

VIRP Intrinsic Value
297.98 EUR
Overvaluation 16%
Intrinsic Value
Price

See Also

What is Virbac SA's Pre-Tax Income?
Pre-Tax Income
529m EUR

Based on the financial report for Jun 30, 2025, Virbac SA's Pre-Tax Income amounts to 529m EUR.

What is Virbac SA's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 10Y
26%

Over the last year, the Pre-Tax Income growth was 156%. The average annual Pre-Tax Income growth rates for Virbac SA have been 47% over the past three years , 39% over the past five years , and 26% over the past ten years .

Back to Top